This most recent twist from the Lykos Therapeutics saga threatens A significant overhaul of the business’s strategy and way, with Musk ally and billionaire investor Antonio Gracias showing to choose to choose the corporate back towards its nonprofit drug development roots and a far more Doblinite philosophy.Patent programs are secret for eighteen